Browse News
Filter News
Found 15 articles
-
Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan
4/19/2022
Takeda announced that it has received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare for Nuvaxovid® Intramuscular Injection, a novel recombinant protein-based COVID-19 vaccine, for primary and booster immunization in individuals aged 18 and older.
-
Takeda Announces Approval of Moderna’s COVID-19 Vaccine in Japan
5/21/2021
Takeda Pharmaceutical Company Limited announced that the Ministry of Health, Labour and Welfare granted special approval under article 14-3 of the Pharmaceuticals and Medical Devices Act for emergency use of Moderna’s mRNA COVID-19 vaccine, TAK-919, now known as COVID-19 Vaccine Moderna Intramuscular Injection, in Japan.
-
Quantum Leap Healthcare Collaborative Concludes Cenicriviroc Not Likely to Reduce Time to Recovery or Mortality in Critically Ill Patients in I-SPY COVID Trial
4/28/2021
Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, today announced that cenicriviroc (CVC) has been dropped from the trial due to futility, based on the low likelihood of success.
-
I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Suggests Addition of Icatibant is Unlikely to Impact Critically Ill COVID-19 Patients
4/15/2021
The I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative (QLHC), was designed to rapidly screen agents that show promise for reducing the time to recovery (defined as reduction in oxygen demand) by approximately 50% or risk of mortality in critically ill COVID-19 patients.
-
Takeda and IDT Support Manufacturing of Johnson & Johnson’s COVID-19 Vaccine
3/15/2021
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced a mutual agreement with IDT Biologika GmbH (“IDT”), a contract development and manufacturing organization, to utilize capacity at IDT previously reserved for Takeda’s dengue vaccine candidate (TAK-003) to manufacture the single-shot COVID-19 vaccine
-
Quantum Leap Healthcare Collaborative Concludes Apremilast Not Likely to Reduce Time to Recovery or Mortality in Critically Ill Patients in I-SPY COVID Trial
3/12/2021
Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, announced that apremilast (Otezla), made by Amgen, has been dropped for futility
-
Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax’ and Moderna’s COVID-19 Vaccine Candidates in Japan
2/24/2021
Takeda is making two COVID-19 vaccines available in Japan, by manufacturing Novavax’ recombinant vaccine candidate and by distributing Moderna’s mRNA vaccine candidate, with the support of the Japanese Government
-
World's Leading Life Science Companies Now Enrolling COMMUNITY, A Global, Platform Trial For Hospitalized Patients With COVID-19
11/30/2020
A range of therapeutics will be evaluated for their potential efficacy and safety relative to the condition severity of patients hospitalized with COVID-19
-
Takeda FY2020 H1 Results Demonstrate Portfolio Resilience; Confirms Full-Year Management Guidance & Raises Forecasts for Free Cash Flow, Reported OP & Reported EPS
10/29/2020
FY2020 H1 results driven by growth of global brands (e.g. Entyvio +25.8% YOY, TAKHZYRO +45.5% YOY, NINLARO + 19.2% YOY); generated strong margins and cash flow
-
Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan
10/29/2020
Three-way agreement among Takeda, Moderna and the Government of Japan’s Ministry of Health Labour and Welfare (MHLW) to bring Moderna’s COVID-19 vaccine candidate (mRNA-1273) to Japan
-
Takeda has entered into a five-year agreement with Accenture and Amazon Web Services (AWS) to support the Tokyo-based pharmaceutical company in moving 80% of its applications to the “cloud” and modernizing the company’s research tools.
-
Takeda Accelerates Digital Transformation with Accenture and AWS
10/13/2020
Collaboration will leverage cloud and data-driven insights to accelerate drug development, increase operational agility, reduce technology costs and develop the workforce of the future
-
Clinical Catch-Up: August 3-7
8/10/2020
It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look. -
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 3, 2020.
-
Members Of The COVID R&D Alliance And Quantum Leap Healthcare Collaborative Enroll First Patients In I-SPY COVID Trial
8/3/2020
I-SPY COVID will evaluate the impact of cenicriviroc, Otezla®, and Firazyr® on inflammatory response in COVID-19 patients